Gilead’s 'unbundled' dive into Patent Pool clarifies royalty-based approach
This article was originally published in Scrip
Executive Summary
The Medicines Patent Pool, which recently signed its first license pact with Gilead Sciences for five products for HIV and hepatitis B, admits that the geographical scope of the agreement is one area that could be improved, but believes that with two of Gilead's products likely to be patented in India, a royalty-based licence for these is not controversial.